Having trouble accessing articles? Reset your cache.

Nov. 11 SITC Roundup: Celyad's first clinical data for allogeneic CAR Ts, plus Vaccibody and Nektar

Celyad reports no GvHD, two PRs in allogeneic CAR T trial
Newly presented data from a Phase I trial of an allogeneic CAR T from Celyad S.A. (Euronext:CYAD; NASDAQ:CYAD) showed that among 12 patients with metastatic colorectal

Read the full 366 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE